ABL Bio FCF/Dettes

Que fait ABL Bio ? ABL Bio Inc is a biotechnology company based in Seongnam, South Korea, operating within the healthcare sector. The company focuses on developing therapeutic drugs for immuno-oncology and neurodegenerative diseases. Founded through an IPO on December 19, 2018, ABL Bio has grown to employ approximately 90 people. Its research and development efforts include a range of advanced antibody-based therapies such as anti-angiogenesis antibodies, anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, and antibody-drug conjugates (ADCs). The company's headquarters are located in Seongnam, Gyeonggi-Do, and it maintains a corporate website at http://www.ablbio.com/. ABL Bio Inc is listed on the Korean stock market with the ticker 298380.KQ and ISIN KR7298380007. The company's product portfolio reflects its commitment to innovative approaches in treating complex medical conditions, particularly in the fields of cancer and neurological disorders. Its development pipeline includes multiple antibody-based therapeutic candidates designed to target specific disease mechanisms with precision. ABL Bio operates as a publicly traded entity, providing transparency through its financial disclosures and market listings. The company's focus on immuno-oncology suggests a strategic emphasis on leveraging the immune system to combat cancer, while its work on neurodegenerative diseases indicates a parallel effort to address conditions such as Alzheimer's or Parkinson's disease. The company's website serves as a primary resource for further information on its research and development activities. ABL Bio est l'une des entreprises les plus populaires sur Eulerpool.